Quarterly report pursuant to Section 13 or 15(d)

Supplemental Information (Tables)

v3.24.1.1.u2
Supplemental Information (Tables)
 3 Months Ended
Mar. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Schedules of Concentration Risk The following table sets forth our concentration of accounts receivable, net of specific allowances for doubtful accounts.
March 31, 2024 December 31, 2023
Customer A 36  % 43  %
Customer B 14  % 16  %
Customer C 4  % 12  %
The following table sets forth our concentration of revenue sources as a percentage of total net revenues:
Three Months Ended March 31,
2024 2023
Customer A 33  % 5  %
Customer B 4  % 30  %
Customer D 14  % 22  %
Schedule of Disposal Group, Including Discontinued Operations
A summary of the Lyte discontinued operation in the condensed consolidated statement of operations and comprehensive loss for the three months ended March 31, 2023 is set forth below:
Net revenues $ 3,403 
Cost of revenues 3,115 
Gross profit 288 
Operating expenses:
Sales and marketing 272 
General and administrative 570 
Research and development 3 
Total operating expenses 845 
Operating loss $ (557)
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share
The following table sets forth common stock equivalents that have been excluded from the computation of dilutive weighted average shares outstanding as their inclusion would have been anti-dilutive:
Three Months Ended March 31,
2024 2023
Warrants — 132,651 
Options 13,011 17,341 
Restricted stock units 78,387 109,605
Total 91,398 259,597